Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. The company markets MACI® (autologous cultured chondrocytes on porcine collagen membrane), a third generation autologous cellularized scaffold product that is indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the adult knee, with or without bone involvement.

From Your Cells to MACI

MACI Detail Aid